Cargando…

Making clinical decisions based on measurable residual disease improves the outcome in multiple myeloma

The assessment of measurable residual disease (MRD) in bone marrow has proven of prognostic relevance in patients with multiple myeloma (MM). Nevertheless, and unlike other hematologic malignancies, the use of MRD results to make clinical decisions in MM has been underexplored to date. In this retro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Martinez-Lopez, Joaquin, Alonso, Rafael, Wong, Sandy W., Rios, Rafael, Shah, Nina, Ruiz-Heredia, Yanira, Sanchez-Pina, Jose Maria, Sanchez, Ricardo, Bahri, Natasha, Zamanillo, Irene, Poza, Maria, Buenache, Natalia, Encinas, Cristina, Juarez, Luis, Miras, Fatima, Collado, Luis, Barrio, Santiago, Martin, Thomas, Cedena, Maria Teresa, Wolf, Jeffrey
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8369640/ https://www.ncbi.nlm.nih.gov/pubmed/34404440 http://dx.doi.org/10.1186/s13045-021-01135-w

Ejemplares similares

The clinical significance of stringent complete response in multiple myeloma is surpassed by minimal residual disease measurements
por: Cedena, Maria-Teresa, et al.
Publicado: (2020)

P702: APPLICATION OF NEXT GENERATION SEQUENCING (NGS) FOR MINIMAL RESIDUAL DISEASE (MRD) AND CHIMERISM MONITORING IN MYELODYSPLASTIC SYNDROME (MDS) AFTER ALLOGENIC STEM CELL TRANSPLANTATION (ASCT)
por: Zamanillo, Irene, et al.
Publicado: (2023)

Impact of IPSS-M implementation in real-life clinical practice
por: Zamanillo, Irene, et al.
Publicado: (2023)

Clinical Outcomes of Patients with Multiple Myeloma after Daratumumab Failure
por: Zamanillo, Irene, et al.
Publicado: (2023)

Genetic Alterations in Members of the Proteasome 26S Subunit, AAA-ATPase (PSMC) Gene Family in the Light of Proteasome Inhibitor Resistance in Multiple Myeloma
por: Haertle, Larissa, et al.
Publicado: (2023)

P840: ASSESSMENT OF CONVENTIONAL TRANSLOCATIONS AND IG REARRANGEMENTS IN THE DIAGNOSIS OF MULTIPLE MYELOMA PATIENTS USING A TARGETED CAPTURE-HYBRIDIZATION RNA SEQUENCING PANEL.
por: Buenache Cuenda, Natalia, et al.
Publicado: (2023)

PB1781: THE APPLICATION OF CF-DNA FOR NGS MRD STUDIES IN PATIENTS WITH LMA IMPROVES THE SENSITIVITY OF THE METHOD WITH RESPECT TO CTC.
por: Sánchez-Redondo, Noemí Álvarez, et al.
Publicado: (2023)

NGS-Based Molecular Karyotyping of Multiple Myeloma: Results from the GEM12 Clinical Trial
por: Rosa-Rosa, Juan Manuel, et al.
Publicado: (2022)

Measurable residual disease in multiple myeloma: ready for clinical practice?
por: Burgos, Leire, et al.
Publicado: (2020)

Myc-Related Mitochondrial Activity as a Novel Target for Multiple Myeloma
por: Ortiz-Ruiz, Alejandra, et al.
Publicado: (2021)

Ibrutinib effect in acquired von Willebrand syndrome secondary to Waldenström macroglobulinemia
por: Poza, María, et al.
Publicado: (2021)

The Current Role of the Heavy/Light Chain Assay in the Diagnosis, Prognosis and Monitoring of Multiple Myeloma: An Evidence-Based Approach
por: Ríos-Tamayo, Rafael, et al.
Publicado: (2021)

Pathogenetic and Prognostic Implications of Increased Mitochondrial Content in Multiple Myeloma
por: Ruiz-Heredia, Yanira, et al.
Publicado: (2021)

P845: IDENTIFICATION OF MULTIPLE MYELOMA BIOMARKERS VIA LIQUID BIOPSY BASED ON CELL-FREE DNA USING A CAPTURE-HYBRIDIZATION PANEL
por: Buenache Cuenda, N., et al.
Publicado: (2022)

A novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia
por: Onecha, Esther, et al.
Publicado: (2019)

The changing landscape of relapsed and/or refractory multiple myeloma (MM): fundamentals and controversies
por: Hernández-Rivas, José-Ángel, et al.
Publicado: (2022)

Identification of Immunoglobulin Gene Rearrangement Biomarkers in Multiple Myeloma through cfDNA-Based Liquid Biopsy Using tchDNA-Seq
por: Buenache, Natalia, et al.
Publicado: (2023)

S256: HLA-E/NKG2A CHECKPOINT DRIVES MULTIPLE MYELOMA RESISTANCE TO CAR-NK THERAPY
por: Encinas, Jessica, et al.
Publicado: (2023)

Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma
por: Puig, Noemí, et al.
Publicado: (2022)

P948: REAL-WORLD EVIDENCE OF BISPHOSPHONATES FOR MULTIPLE MYELOMA
por: Muñoz, Maria Nieves Lopez, et al.
Publicado: (2023)

Reference Values to Assess Hemodilution and Warn of Potential False-Negative Minimal Residual Disease Results in Myeloma
por: Puig, Noemí, et al.
Publicado: (2021)

Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients
por: Jiménez-Ubieto, Ana, et al.
Publicado: (2023)

Corrigendum: Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients
por: Jiménez-Ubieto, Ana, et al.
Publicado: (2023)

Pomalidomide in the treatment of multiple myeloma: design, development and place in therapy
por: Ríos-Tamayo, Rafael, et al.
Publicado: (2017)

Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma
por: Martinez-Lopez, J, et al.
Publicado: (2017)

The Minimal Residual Disease Using Liquid Biopsies in Hematological Malignancies
por: Colmenares, Rafael, et al.
Publicado: (2022)

Radiomics analysis of bone marrow biopsy locations in [(18)F]FDG PET/CT images for measurable residual disease assessment in multiple myeloma
por: Milara, Eva, et al.
Publicado: (2023)

Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma
por: Medina, Alejandro, et al.
Publicado: (2020)

Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature
por: Rodríguez-Otero, Paula, et al.
Publicado: (2019)

A novel targeted RNA-Seq panel identifies a subset of adult patients with acute lymphoblastic leukemia with BCR-ABL1-like characteristics
por: Sánchez, Ricardo, et al.
Publicado: (2020)

P1328: SUCCESFUL TREATMENT OF GRAFT FAILURE IN AUTOLOGOUS STEM CELL TRANSPLANTATION WITH CYCLOSPORINE
por: Cubillas, D., et al.
Publicado: (2022)

Genetic Profiling of Cell-Free DNA in Liquid Biopsies: A Complementary Tool for the Diagnosis of B-Cell Lymphomas and the Surveillance of Measurable Residual Disease
por: Figaredo, Gloria, et al.
Publicado: (2023)

Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial
por: Puig, Noemi, et al.
Publicado: (2021)

Unsupervised machine learning improves risk stratification in newly diagnosed multiple myeloma: an analysis of the Spanish Myeloma Group
por: Mosquera Orgueira, Adrian, et al.
Publicado: (2022)

Results of an Early Access Treatment Protocol of Daratumumab Monotherapy in Spanish Patients With Relapsed or Refractory Multiple Myeloma
por: Alegre, Adrián, et al.
Publicado: (2020)

Impact of COVID-19 in patients with multiple myeloma based on a global data network
por: Martinez-Lopez, J., et al.
Publicado: (2021)

The Role of Tumor Microenvironment in Multiple Myeloma Development and Progression
por: García-Ortiz, Almudena, et al.
Publicado: (2021)

Minimal Residual Disease in Multiple Myeloma: Past, Present, and Future
por: Medina-Herrera, Alejandro, et al.
Publicado: (2023)

PB2091: INFLUENCE OF HISTOLOGICAL GRADE IN CLINICAL CHARACTERISTICS AND LONG-TERM OUTCOME OF FOLICULAR LYMPHOMA
por: Zamanillo, I., et al.
Publicado: (2022)

Large-scale real-life analysis of survival and usage of therapies in multiple myeloma
por: Lopez-Muñoz, N., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_5bk8p1v744otl9k76286nqtgn7